Leflunomide/methylprednisolone sodium succinate/pegloticase
- PDF / 169,579 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 110 Downloads / 192 Views
1 S
Leflunomide/methylprednisolone sodium succinate/pegloticase Increased alanine aminotransferase levels, loss of consciousness and wooziness: 2 case reports
A retrospective study of 10 patients with uncontrolled gout described two patients [ages and sexes not stated], of whom, one patient developed increased alanine aminotransferase levels during treatment with leflunomide and pegloticase for uncontrolled gout, while the remaining one patient developed loss of consciousness and wooziness during treatment with methylprednisolone sodium succinate as a prophylactic therapy [not all routes, dosages and outcomes stated; durations of treatments to reactions onsets not stated]. The patients, who had an uncontrolled gout, started receiving treatment with oral leflunomide 20mg daily and pegloticase 8 mg/ infusion (scheduled). Prior to each infusion of pegloticase, the patients received a standard prophylaxis regimen of fexofenadine the night before and day of infusion, and methylprednisolone-sodium-succinate [solumedrol] on the day of infusion. Thereafter, one of these patients developed mild and transient increase in alanine aminotransferase (ALT), which was attributed to leflunomide and pegloticase, and another patient developed loss of consciousness and wooziness prior to pegloticase infusion due to methylprednisolone sodium succinate. The patient with loss of consciousness and wooziness required emergency care. Masri K, et al. Leflunomide co-therapy with pegloticase in uncontrolled gout. Annals of the Rheumatic Diseases 79 (Suppl.): 454 abstr. THU0434, Jun 2020. Available from: 803516172 URL: https://ard.bmj.com/content/79/Suppl_1/454.3 [abstract]
0114-9954/20/1831-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 21 Nov 2020 No. 1831
Data Loading...
